The role of genetics in inhibitor formation

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 500-504

  Gill, Joan Cox ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING INHIBITOR;

CONFERENCE PAPER; GENETICS; HEMOPHILIA A; HEREDITY; PRIORITY JOURNAL;

EID: 0032742545     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615871     Document Type: Conference Paper

References (43)

1. Gill JC. Therapy of factor VIII deficiency. Semin Thromb Haemost. 1993;19:1-12.
2. Kasper C. Treatment of factor VIII inhibitors. Prog Hemost Thromb. 1989;9:57-86.
3. McMillan CW, Shapiro SS, Whitehurst D. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. Blood. 1988;71:344-348.
4. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594-598.
5. Sultan Y, for the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost. 1992;67:600-602.
6. Lusher J. Management of patients with factor VIII inhibitors. Transfus Med Rev. 1987;1:123-130.
7. Schwarzinger I, Pablinger I, Korninger C, Haschke G, Kundi M, Niessner H, Lechner K. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol. 1987;24:241-245.
8. Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood. 1993;81:3332-3335.
9. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort LM. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet. 1993;342:462-464.
10. de Biasi R, Rocino A, Papa L, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost. 1994;71:544-547.
11. Guerois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos A, Negrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M, Derlon A, Berthier A, Gaillard S, Bertrand M. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost. 1995;73:215-218.
12. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M, for the Recombinant Study Group. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood. 1994;83:2428-2435.
13. Lusher J, Arkin S, Abildgaard C, Schwartz RS, for the Kogenate Previously Untreated Patient Study Group. Recombinant factor VII for the treatment of previously untreated patients with hemophilia A. N Engl J Med. 1993;328:453-459.
14. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood. 1988;71:344-348.
15. Hoyer LW. The incidence of factor VII inhibitors in patients with severe hemophilia A, In : Aledort LM, ed. Inhibitors to Coagulation Factors. Plenum Press, New York; 1995:35.
16. Peerlinck K, Amout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost. 1997;77:80-86.
17. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PFW, for the Dutch Haemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused haemophilia A patients in The Netherlands. Blood. 1993;81:2180-2186.
18. Bray GL, Kroner BL, Arkin S, Aledort LM, Hilgartner M, Eyster ME, Ragni MV, Goedert JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus Type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol. 1993;42:375-379.
19. European Study Group of Factor VIII Antibody. Development of factor VIII antibody in haemophilic monozygotic twins. Scan J Haematol. 1979;23:64-68.
20. Shapiro SS. Genetic predisposition to inhibitor formation. Prog Clin Biol Res. 1984;150:45-55.
21. Frommel D, Allain JP. Genetic predisposition to develop factor VIII antibody in classic hemophilia. Clin Immuno Immunopathol. 1977;8:34-38.
22. Giles AR, Tinlin S, Hoogendoom H, Greenwood P, Greenwood R. Development of factor VIII:C antibodies in dogs with hemophilia A (Factor VIII:C deficiency). Blood. 1984;63:451-456.
23. Tinlin S, Webster S, Giles AR. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten-year longitudinal study. Thromb Haemost. 1993;69:21-24.
24. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J. Haemophilia A. Mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74:1402-1406.
25. Tuddenham EGD, McVey JH. The genetic basis of inhibitor development in haemophilia A. Haemophilia. 1998;4:543-545.
26. Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, Ketterling RP, Kazazian JJ, Negrier C, Vinciguerra C, Gitschier J, Goossens M, Girodon E, Ghanem M, Plassa F, Lavergne JM, Vidaud M, Costa JM, Laurian Y, Lin S, Lin S, Shen M, Lillicrap D, Taylor SAM, Windsor S, Valleix SB, Nafa K, Sultan Y, Delpech M, Vnencak-Jones CL, Phillips III JA, Ljung RCR, Koumbarelis E, Gialeraki A, Mandalaki T, Jenkins PV, Collins PW, Pasi J, Goodeve AC, Peake IR, Preston FE, Schwartz M, Scheibel E, Ingerslev J, Cooper DN, Millar DS, Kakkar VV, Giannelli F, Naylor JA, Tizzano EF, Baiget M, Domenech M, Altisent C, Tusell J, Beneyto M, Lorenzo JI, Gaucher C, Mazurier C, Peerlinck K, Matthijs G, Cassiman JJ, Vermylen J, Mon PG, Acquila M, Caprino D, Inaba J. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86:2206-2212.
27. Gill JC, Lessinger C, Kasper C, Sexhauer C, Inwood M, Cohen A, for the HRS Inhibitor Registry Investigators. Hemophilia inhibitors in the 80s and 90s: a first look at the Hemophilia Research Society Inhibitor Registry. Blood. 1996;88:330a.
28. Lavergne JM, Meyer D, Reisner H. Characterization of human anti-factor VIII antibodies purified by immune complex formation. Blood. 1976;48:931-939.
29. Shapiro SS. Characterization of factor VIII antibodies. Ann N Y Acad Sci. 1975; 240:350-361.
30. Allain JP, Frommel D. Antibodies to factor VIII: specificity and kinetics of iso- and hetero-antibodies in hemophilia A. Blood. 1974;44:313-322.
31. Fulcher CA, De Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclasss and FVIII polypeptide specificity determined by immunoblotting. Blood. 1987;69:1475-1480.
32. Gilles JG, Armout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophilic patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood. 1993;82:2452.
33. Schultz CL, Coffman RL. Control of isotype switching by T cells and cytokines. Curr Opin Immunol. 1991;3:350-354.
34. Punnonen J, Aversa G, Cocks BG, McKenzie ANJ, Menon S, Zurawski G, de Waal Malefyt R, de Vries JD. Interleukin-13 induces interleukin-4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA. 1998;90:3730.
35. Larocque R, Robinson MA. Diversity in the human T cell receptor beta chain. Hum Immunol. 1996;48:3-11.
36. Shevach EM, Rosenthal AS. Function of macrophages in antigen recognition by guinea pig T lymphocyptes. II. Role of the macrophage in the regulation of genetic control of the immune response. J Exp Med. 1973;138:1213-1229.
37. Mayr WR, Lechner K, Niessner H, Pabinger-Fasching I. HLA-DR and factor VIII antibodies in hemophilia A. Thromb Haemost. 1984;51:293.
38. Lippert LE, Fisher LM, Schook LB. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A. Thromb Haemost. 1990;64:564-568.
39. Aly AM, Aledort LM, Lee TD, Hoyer LW. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol. 1990;76:238-241.
40. Hay CRM, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FGH, Preston FE, Peake IR, for the UKHC-DO Inhibitor Working Party. HLA class II profile. A weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost. 1997;77:234.
41. Oldenburg J, Picard J, Schwaab R, Brackman HH, Tuddenham EGD, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost. 1997;77:238-242.
42. Theofilopoulos A. The basis of autoimmunity: part II. Genetic predisposition. Immunol Today. 1995;16:150-159.
43. Hershey GK, Friedrich M, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the subunit of the interleukin-4 receptor. N Engl J Med. 1997;337:1720-1725.